Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiri Vencovsky

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Arthritis Research & Therapy|April 20, 2019
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trialPeter C Taylor, Didier Saurigny, Jiri Vencovsky, et al.
Rheumatology (Oxford, England)|February 21, 2012
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTXErnest Choy, Frank McKenna, Jiri Vencovsky, et al.
Nature Reviews. Disease Primers|December 3, 2021
Idiopathic inflammatory myopathiesIngrid E Lundberg, Manabu Fujimoto, Jiri Vencovsky, et al.
Arthritis Research & Therapy|June 4, 2016
MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritisVeronika Hruskova, Romana Jandova, Lucia Vernerova, et al.
Rheumatology (Oxford, England)|November 16, 2019
Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositisZoe Betteridge, Hector Chinoy, Jiri Vencovsky, et al.
Annals of the Rheumatic Diseases|July 31, 2014
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapyPeter C Taylor, Mark C Genovese, Mike Greenwood, et al.
Arthritis and Rheumatism|November 1, 2008
Reliability and validity of the myositis disease activity assessment toolShabina M Sultan, Elizabeth Allen, Chester V Oddis, et al.
Medicine|June 27, 2012
Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literatureAne Labirua-Iturburu, Albert Selva-O'Callaghan, Melinda Vincze, et al.
Diagnostics (Basel, Switzerland)|January 21, 2022
The Prevalence of MRI-Defined Sacroiliitis and Classification of Spondyloarthritis in Patients with Acute Anterior Uveitis: A Longitudinal Single-Centre Cohort StudyKristyna Bubova, Lenka Hasikova, Katerina Mintalova, et al.
Clinical and Experimental Rheumatology|November 18, 2015
Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activityMartina Misunova, Gabriela Salinas-Riester, Susanne Luthin, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Arthritis Research & Therapy|April 20, 2019
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trialPeter C Taylor, Didier Saurigny, Jiri Vencovsky, et al.
Rheumatology (Oxford, England)|February 21, 2012
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTXErnest Choy, Frank McKenna, Jiri Vencovsky, et al.
Nature Reviews. Disease Primers|December 3, 2021
Idiopathic inflammatory myopathiesIngrid E Lundberg, Manabu Fujimoto, Jiri Vencovsky, et al.
Arthritis Research & Therapy|June 4, 2016
MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritisVeronika Hruskova, Romana Jandova, Lucia Vernerova, et al.
Rheumatology (Oxford, England)|November 16, 2019
Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositisZoe Betteridge, Hector Chinoy, Jiri Vencovsky, et al.
Annals of the Rheumatic Diseases|July 31, 2014
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapyPeter C Taylor, Mark C Genovese, Mike Greenwood, et al.
Arthritis and Rheumatism|November 1, 2008
Reliability and validity of the myositis disease activity assessment toolShabina M Sultan, Elizabeth Allen, Chester V Oddis, et al.
Medicine|June 27, 2012
Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literatureAne Labirua-Iturburu, Albert Selva-O'Callaghan, Melinda Vincze, et al.
Diagnostics (Basel, Switzerland)|January 21, 2022
The Prevalence of MRI-Defined Sacroiliitis and Classification of Spondyloarthritis in Patients with Acute Anterior Uveitis: A Longitudinal Single-Centre Cohort StudyKristyna Bubova, Lenka Hasikova, Katerina Mintalova, et al.
Clinical and Experimental Rheumatology|November 18, 2015
Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activityMartina Misunova, Gabriela Salinas-Riester, Susanne Luthin, et al.
Pageof 7